share_log

Top Biopharma Brands Reach Audiences 10x More Qualified With Veeva Crossix Prime Segments

Top Biopharma Brands Reach Audiences 10x More Qualified With Veeva Crossix Prime Segments

顶级生物制药品牌借助Veeva Crossix Prime细分市场吸引的受众人数增加了10倍
PR Newswire ·  04/23 07:03

Veeva Crossix helps 16 of the top 20 biopharmas more efficiently reach clinically relevant patients

Veeva Crossix帮助排名前20的生物制药中的16家更有效地覆盖临床相关患者

PLEASANTON, Calif., April 23, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that 16 of the top 20 biopharmas are increasing media efficiency with Veeva Crossix Prime Segments, privacy-safe data helping life sciences brands reach highly-qualified health audiences. Since launching in April 2023, Veeva Crossix Prime Segments have helped top biopharmas reach consumers that are 10 times more qualified than standard health audience segments through digital media campaigns.

加利福尼亚州普莱森顿,2024年4月23日 /PRNewswire/ — Veeva Systems(纽约证券交易所代码:VEEV)今天宣布,排名前20的生物制药公司中有16家正在通过Veeva Crossix Prime细分市场提高媒体效率,隐私安全数据帮助生命科学品牌吸引高素质的健康受众。自2023年4月推出以来,Veeva Crossix Prime Segments通过数字媒体宣传帮助顶级生物制药公司吸引了比标准健康受众群高10倍的合格消费者。

"By using Veeva Crossix Prime Segments we have been able to reach much more precise patient populations in our targeted campaigns," said Scott Carberry, product director for IMBRUVICA, Johnson & Johnson. "Working with a trusted partner like Veeva Crossix affords us a breadth of targeting capabilities, and we've seen success reaching both treatment-naive as well as specific treating for adherence audiences."

强生公司IMBRUVICA产品总监斯科特·卡伯里表示:“通过使用Veeva Crossix Prime Segments,我们能够在有针对性的活动中覆盖更精确的患者群体。”“与Veeva Crossix这样值得信赖的合作伙伴合作为我们提供了广泛的靶向能力,而且我们已经看到,针对依从性受众的初始治疗和特定治疗都取得了成功。”

Veeva Crossix's privacy-safe health audience segments can help marketers achieve multiple campaign goals across any channel. Marketing teams can leverage Veeva Crossix Prime Segments to reach precise patient audiences and Veeva Crossix Reach Segments for broad awareness and ROI at scale.

Veeva Crossix的隐私安全健康受众细分可以帮助营销人员在任何渠道上实现多个活动目标。营销团队可以利用Veeva Crossix Prime细分市场来吸引精确的患者受众,并利用Veeva Crossix细分市场来获得广泛的知名度和大规模的投资回报率。

"A diverse set of health brands are using Veeva Crossix Prime Segments to reach their most qualified audiences — from broad treatment categories to rare diseases," said Jessica Daigle, head of Veeva Crossix Audience Segments. "Veeva Crossix is committed to delivering advanced solutions to help brands reach patients when it matters most."

Veeva Crossix受众细分市场负责人杰西卡·戴格尔表示:“从广泛的治疗类别到罕见疾病,各种各样的健康品牌正在使用Veeva Crossix的Prime细分市场来吸引最合格的受众。”“Veeva Crossix致力于提供先进的解决方案,帮助品牌在最重要的时候为患者提供服务。”

Veeva Crossix Prime Segments are custom-built to reach an advertiser's most qualified audience in a privacy-safe, HIPAA-compliant way. With data privacy embedded at its core, patented Veeva Crossix SafeMine technology ensures that Veeva Crossix Prime and Reach Segments protect patient privacy and are compliant with all applicable laws and regulations.

Veeva Crossix Prime Segments是量身定制的,旨在以隐私安全、符合HIPAA的方式吸引广告商最合格的受众。Veeva Crossix SafeMine专利技术以数据隐私为核心,可确保Veeva Crossix Prime和Reach Segments保护患者隐私,并遵守所有适用的法律法规。

Learn more about using data and analytics to improve marketing effectiveness at Veeva Commercial Summit in Boston, May 7-8. Life sciences industry professionals can register at veeva.com/CommercialSummit.

在5月7日至8日于波士顿举行的Veeva商业峰会上,了解有关使用数据和分析提高营销效率的更多信息。生命科学行业的专业人士可以在Veeva.com/CommercialSummit上注册。

Additional Information
For more on Veeva Crossix Prime Segments, visit: veeva.com/PrimeSegments Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

附加信息
有关 Veeva Crossix Prime 细分市场的更多信息,请访问:veeva.com/PrimeSegments 在领英上与 Veeva 联系:linkedin.com/company/veeva-systems

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

关于 Veeva 系统公司
Veeva是生命科学行业云软件领域的全球领导者。Veeva致力于创新、产品卓越和客户成功,为1,000多家客户提供服务,包括全球最大的生物制药公司和新兴生物技术公司。作为一家公益公司,Veeva致力于平衡所有利益相关者的利益,包括客户、员工、股东及其所服务的行业。欲了解更多信息,请访问 veeva.com。

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.

Veeva 前瞻性声明
本新闻稿包含有关Veeva产品和服务以及使用我们的产品和服务的预期结果或收益的前瞻性陈述。这些陈述基于我们当前的预期。实际结果可能与本新闻稿中提供的结果存在重大差异,我们没有义务更新此类声明。有许多风险可能会对我们的业绩产生负面影响,包括我们在截至2024年1月31日的财年10-K表中披露的风险和不确定性,你可以找到这些风险和不确定性 这里 (可能影响我们业务的风险摘要见第 9 页和第 10 页),以及我们随后提交的美国证券交易委员会文件,您可以访问这些文件 sec.gov

Contact:
Alison Borris
Veeva Systems
925-226-8821
[email protected]

联系人:
艾莉森·博里斯
Veeva 系统
925-226-8821
[电子邮件保护]

SOURCE Veeva Systems

来源 Veeva Syst

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发